please respond to 2 peers post in single line spacing .
question for week 4 is
Preparing the Collaboration Café
Follow these guidelines when completing each component of the collaboration café. Contact your course faculty if you have questions.
General Instructions
During the past four weeks, you have examined conditions affecting the immune, hematologic, cardiovascular, pulmonary, and renal systems. Some conditions can affect all of these conditions, including autoimmune disorders like systemic lupus erythematosus (SLE) that cause inflammation in multiple body systems. Follow the steps below to analyze the effects of SLE on various body systems.
Step 1: Review your assigned body system from weeks 1-4. Your assignment is based on the first letter of your last name in the chart below.
Last Name
Body System
A – F
Immune System
G – K
Hematologic System
L – P
Cardiovascular System
Q – U
Pulmonary System
V – Z
Renal System
Step 2: Reflect on how SLE impacts your assigned body system.
Step 3: Answer the discussion prompts below with explanation and detail, providing complete references for all citations.
Step 4: Reply to a peer with a different assigned body system.
Include the following sections:
1. Application of Course Knowledge: Answer all questions/criteria with explanations and detail.
Describe the specific pathophysiological processes in SLE that lead to the manifestations observed in your assigned body system. How does SLE affect your assigned body system?
Discuss the symptoms and clinical manifestations of SLE on your assigned body system. How do these symptoms impact the clientâ€s function and quality of life? Can changes in your assigned body system affect or be affected by other body systems in clients with SLE?
Discuss the diagnostic tests used to diagnose SLE-related complications in your body system. What challenges are associated with diagnosing SLE if only looking at your assigned body system?
Explore the current treatments for managing SLE symptoms associated with your assigned body system. What are the goals of these treatments and how effective are they in mitigating the impact of SLE on the body?
2. Engagement in Meaningful Dialogue: Engage peers by asking questions and offering new insights, applications, perspectives, information, or implications for practice:
Respond to at least one peer.
Respond to a second peer post.
Communicate using respectful, collegial language and terminology appropriate to advanced nursing practice.
3. Professionalism in Communication: Communicate with minimal errors in English grammar, spelling, syntax, and punctuation. 
4. Wednesday Participation Requirement: Provide a substantive response to the collaboration café topic (not a response to a peer) by Wednesday, 11:59 p.m. MT of each week. 
5. Total Participation Requirement: Provide at least three substantive posts (one to the initial question or topic and two to student peers) on two different days during the week.  
Peer 1 post /Karla
Good afternoon Professor and Classmates,
Body System: Immune System
Autoimmune disorder: Systemic Lupus Erythematosus (SLE)
Pathophysiology
Systemic lupus erythematosus (SLE) is a disease of immune tolerance. The immune system is both the target and the cause in another part of the body. Apoptotic cells are not cleared properly. Apoptotic cells are normally cleared without an immune response by phagocytes. In SLE, not clearing apoptotic cells allows extracellular nuclear antigens (such as histones, nucleosomes, double stranded DNA, ribonucleoproteins) to cause an immune response (Accapezzato et al., 2023).
Nucleic acids bind to endosomal Toll-like receptors 7 and 9 on plasmacytoid dendritic cells. This stimulates the production of type I interferons. This interferon response is the hallmark of SLE. Interferon-alpha increases the activation of autoreactive T and B lymphocytes, promotes dendritic cell activation, and perpetuates an inflammatory state (Accapezzato et al., 2023).
There are also failures in central and peripheral tolerance which allow autoreactive T and B cells to escape deletion and anergy. Regulatory T cells are reduced in number and follicular helper T cells are increased. B cells undergo affinity and class switching to autoantigens. IgG autoantibodies are formed and form immune complexes. These immune complexes deposit in tissues, activate the complement system via the classical pathway, and promote neutrophil recruitment. The consumption of complement components (C3 and C4) is useful in diagnosis. Neutrophils also form extracellular traps containing nuclear material which perpetuates the disease process.
Clinical manifestation and Impact
Immune dysfunction in SLE manifests as both autoimmunity and immunodeficiency.
Hematologic manifestations occur in SLE and are related to autoantibody mediated destruction of hematologic cells. Immune thrombocytopenia, leukopenia with lymphopenia, and autoimmune hemolytic anemia can be seen. Lymphadenopathy and splenomegaly are seen due to lymphoproliferation. Fatigue is a very common presenting and persistent complaint in SLE patients. Most patients experience fatigue, and for many patients fatigue is the most impairing symptom. Fatigue is partially due to cytokine mediated effects of cytokines such as IL-6, TNF-alpha, and interferon-alpha on the central nervous system. Fatigue does not do well in correlation to serologic activity. This is important from a clinical standpoint as many patients with laboratory improvement may still have functional impairment. Ignoring this could hurt the patient- provider relationship.
Immunodeficiency is also seen in SLE. Lymphopenia, hyposplenism, impaired neutrophil function, complement deficiency puts patients at risk for opportunistic infections, herpes zoster and encapsulated organisms. Infections are a leading cause of mortality in SLE patients. Immunosuppressive treatment can also increase risk for infection.
Many organ systems are affected. Lupus nephritis is caused by immune complex deposition in glomeruli. Photosensitive rash is caused by immune complex deposition in the skin. Pleurisy and pericarditis are caused by immune complex deposition on serosal surfaces. Thrombosis and pregnancy loss are caused by antiphospholipid antibodies. Atherosclerosis is accelerated in SLE. Cardiovascular risk is significantly higher than can be predicted by traditional risk factors. Other systems also play a role in immune regulation. UV induces keratinocyte apoptosis and flares. Vitamin D deficiency due to sun avoidance can also play a role in immune dysregulation.
Diagnostic tests used to diagnose SLE and Challenges
ANA testing by immunofluorescence is used as an initial screening test for the 2019 EULAR/ACR criteria and requires a titer of 1:80 or higher (Fanouriakis et al., 2021). ANA testing is very sensitive (approximately 98%) but not very specific as many healthy individuals will also test positive.
Anti-double stranded DNA is highly specific and correlates to disease activity and nephritis. Anti-Smith is the most specific autoantibody, however only a small percentage of SLE patients have this antibody. Anti-Ro/SSA and anti-La/SSB have implications for congenital heart block and neonatal lupus. C3 and C4 decrease in active SLE. CBC can detect cytopenias. Antiphospholipid antibodies include anticardiolipin, anti-beta-2 glycoprotein I, and lupus anticoagulant. All can stratify risk for thrombosis.
The main issue in diagnosis is that SLE is not defined by a specific immunologic finding. Serology must be coupled to clinical findings. Autoantibodies can appear years before the clinical presentation of SLE. Drug induced lupus has a specific antihistone antibody. Only looking at immunology can result in both overdiagnosis of ANA positivity without symptoms and under-recognition in patients with primarily organ-specific disease.
Treatment
Hydroxychloroquine is recommended for essentially all patients in SLE. Hydroxychloroquine reduces flares, organ damage, thrombosis and improves survival. Dose should not exceed 5 mg/kg of actual body weight in order to reduce the risk of retinal pathology (Fanouriakis et al., 2021). Glucocorticoids are used to manage acute disease but should be tapered to 7.5 mg prednisone or less. The damage associated with glucocorticoids is dose dependent.
Steroid sparing agents include mycophenolate mofetil, azathioprine and methotrexate. There has also been a shift toward biologics which target B-cell survival and type I interferon signaling. Belimumab targets BLyS and anifrolumab blocks the type I interferon receptor. Both have shown reduced disease activity and a reduction in steroid use in clinical trials (Vital et al., 2022). Voclosporin has also been approved for the treatment of lupus nephritis.
Goals of treatment include low disease activity or remission, prevention of organ damage and flares and minimizing iatrogenic effects. Vaccinations should be given before immunosuppressive treatment is started. Photoprotection is important and cardiovascular risk should also be managed.
References
Accapezzato, D., Caccavale, R., Paroli, M. P., Gioia, C., Nguyen, B. L., Spadea, L., & Paroli, M. (2023). Advances in the pathogenesis and treatment of systemic lupus erythematosus. International Journal of Molecular Sciences, 24(7), 6578. https://doi.org/10.3390/ijms24076578
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021). Update on the diagnosis and management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 80(1), 14-25. https://doi.org/10.1136/annrheumdis-2020-218272
Siegel, C. H., & Sammaritano, L. R. (2024). Systemic lupus erythematosus: A review. JAMA, 331(17), 1480-1491. https://doi.org/10.1001/jama.2024.2315
Vital, E. M., Merrill, J. T., Morand, E. F., Furie, R. A., Bruce, I. N., Tanaka, Y., Manzi, S., Kalunian, K. C., Kalyani, R. N., Streicher, K., Abreu, G., & Tummala, R. (2022). Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE. Annals of the Rheumatic Diseases, 81(7), 951-961. https://doi.org/10.1136/annrheumdis-2021-221425
peer 2post /simrat
Systemic Lupus Erythematosus and the Hematologic System
Pathophysiology of SLE and the Hematologic System
A chronic autoimmune illness called systemic lupus erythematosus (SLE) results in tissue damage and inflammation all over the body due to aberrant immunological activation. The hematologic system is frequently impacted and may include platelets, white blood cells, and red blood cells. Blood cells can be targeted by autoantibodies, which can aid in their demise. Leukopenia, lymphopenia, immune thrombocytopenia, and autoimmune hemolytic anemia are common hematologic symptoms (Alba et al., 2022).
Autoantibodies bind to red blood cells and encourage their destruction in autoimmune hemolytic anemia, which lowers hemoglobin levels and causes anemia. Leukopenia and lymphopenia can also result from SLE due to immune-mediated destruction and altered synthesis of blood cells. Autoantibodies that target platelets can cause thrombocytopenia, which increases the risk of bleeding and platelet loss (Alba et al., 2022; Zuo et al., 2022).
Clinical Manifestations and Impact on Quality of Life
Fatigue, weakness, pallor, dizziness, shortness of breath, recurrent infections, bruising, and bleeding can all be signs of hematologic involvement in SLE. Fatigue and a diminished capacity to carry out daily tasks might arise from anemia’s substantial reduction in oxygen delivery to tissues. While thrombocytopenia can result in petechiae, easy bruising, nosebleeds, or more severe bleeding, leukopenia and lymphopenia may make a person more vulnerable to infections. A client’s quality of life and physical functioning may suffer because of these issues. Work, exercise, domestic chores, and social engagement can all be hampered by weaknesses and exhaustion. Recurrent infections or a fear of bleeding can also limit regular activities and cause emotional stress. Other bodily systems are intimately related to the hematologic system. For instance, because the heart must work harder to supply enough oxygen to tissues, severe anemia can raise cardiovascular workload. Reduced erythropoietin production is another way that renal illness associated with SLE can cause anemia. Additionally, drugs used to treat SLE may raise the risk of infection or inhibit bone marrow function. Hematologic abnormalities in SLE should therefore be assessed in relation to the patient’s overall disease activity and organ involvement.
Diagnostic Testing
A complete blood count (CBC) with differentials is the first step in evaluating hematologic problems in SLE. Anemia, leukopenia, lymphopenia, and thrombocytopenia can all be detected by this test. A reticulocyte count, peripheral blood smear, bilirubin, lactate dehydrogenase (LDH), haptoglobin, and a direct antiglobulin test (DAT or Coombs test) should be performed if anemia is detected. These tests can assist in determining whether immune-mediated hemolysis is the cause of anemia (Alba et al., 2022). Platelet levels should be checked for thrombocytopenia, and further testing might be required to rule out other reasons for low platelet counts. When there is bleeding, coagulation tests might also be necessary. Since antiphospholipid syndrome is linked to SLE and can raise the risk of thrombosis, antiphospholipid antibodies should be assessed. The fact that these results are not unique to SLE makes it difficult to diagnose hematologic abnormalities associated with SLE. Iron deficiency, autoimmune hemolysis, chronic inflammation, kidney illness, blood loss, and drug side effects can all cause anemia. Leukopenia and thrombocytopenia can also have autoimmune, medication-related, or viral causes. Therefore, rather of depending just on a single test aberration, clinicians must take into account the patient’s medications, disease activity, nutritional condition, infection history, and involvement of other organ systems.
Current Treatment and Goals
The exact abnormality and its severity determine how hematologic symptoms are treated. Controlling SLE disease activity, preventing organ damage, treating cytopenias, and enhancing quality of life are the main objectives. Unless contraindicated, hydroxychloroquine is advised for the majority of SLE patients since it helps manage overall disease activity and lessen flare-ups (Fanouriakis et al., 2024). Glucocorticoids are frequently used to inhibit the autoimmune response in cases of severe autoimmune hemolytic anemia or immune thrombocytopenia. Immunosuppressive drugs such azathioprine, mycophenolate, or other treatments may be used to patients who do not respond well or who need steroid-sparing therapy. For severe or refractory hematologic disorders, rituximab may be taken into consideration. The degree of cytopenia, hemorrhage or hemolysis, involvement of other organs, and response to prior therapy all influence the choice of treatment (Alba et al., 2022; Fanouriakis et al., 2024). The degree of illness and the hematologic presentation determine how effective treatment is. Improved blood counts, less symptoms, the avoidance of major problems, and a lower chance of long-term organ damage are all possible with early detection and treatment. Due to the possible negative effects of long-term glucocorticoid treatment, current recommendations focus on establishing remission or minimal disease activity (Fanouriakis et al., 2024).
Conclusion
Due to the autoimmune loss of red blood cells, white blood cells, and platelets, SLE can have a substantial impact on the hematopoietic system. Anemia, leukopenia, lymphopenia, and thrombocytopenia are common symptoms that can result in bleeding, bruises, infections, weakness, and exhaustion. CBC tests and further research depending on the particular anomaly are necessary for diagnosis. Hematologic abnormalities must be assessed in relation to the patient’s overall SLE disease activity and other organ involvement because they can have a variety of causes. Controlling autoimmune activity, treating cytopenias, avoiding complications, and enhancing quality of life are the main goals of treatment. Depending on the degree and kind of hematologic involvement, biologic treatments, corticosteroids, immunosuppressive drugs, and hydroxychloroquine may be employed.
References
Alba, M. A., Karras, A., & Sacré, K. (2022). A practical perspective of the hematologic manifestations of systemic lupus erythematosus. Journal of Clinical Medicine, 11(20), 6090.
https://doi.org/10.3390/jcm11206090
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bertsias, G., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Kouloumas, M., Kuhn, A., Lerstrøm, K., Moroni, G., Mosca, M., Schneider, M., … Boumpas, D. T. (2024). EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 83(1), 15–29.
https://doi.org/10.1136/ard-2023-224762
Zuo, Z., Li, X., Wang, X., Chen, Y., & Zhang, F. (2022). Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment. Journal of Autoimmunity, 132, 102887.
https://doi.org/10.1016/j.jaut.2022.102887
